Prostate Cancer
IFN-gamma increases cancer cells' sensitivity to Fas-mediated death
Published in Gene Therapy Weekly, May 1st, 2003
This could be exploited in gene therapy for prostate cancer, researchers say.
"While human prostate cancers and cell lines express Fas, most of these cell lines are resistant to Fas-mediated death. ... [W]e addressed the ability of IFN-gamma to influence Fas-mediated cell death in prostate cancer cells," said W.A. Selleck and colleagues.
When they exposed human cell lines LNCaP and PC3 and the mouse cell line RM-1 in vitro to agonist anti-Fas antibody and/or soluble Fas ligand, only PC3 cells died, the researchers...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2003-05-01)
More Articles from Gene Therapy Weekly
- Ischemic Heart Disease
IGF gene transfer protects cardiomyocytes from apoptosis, boosts angiogenesis - Vector Development
Intravenous negative-strand RNA viral vectors can be used for gene replacement - Erectile Dysfunction
Gene therapy improves condition in rat study - Gene Delivery
Method offers selective protection of internal restriction endonuclease sites - Stem Cell-Based Gene Therapy
HSCs from different sources have different transduction efficiencies - Transgenic Cell Therapy
Neovascularized organoid can deliver proteins in nonmyeloablated recipients - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
